Your browser doesn't support javascript.
loading
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K Ray; Criswell, Susan R; Danielsen, Erik H; Gandor, Florin; Jia, Jia; Kimber, Thomas E; Mochizuki, Hideki; Robieson, Weining Z; Spiegel, Amy M; Standaert, David G; Talapala, Saritha; Facheris, Maurizio F; Fung, Victor S C.
Afiliação
  • Aldred J; Selkirk Neurology and Inland Northwest Research, 610 S Sherman St, Spokane, WA, 99202, USA. JAldred@selkirkneurology.com.
  • Freire-Alvarez E; Neurology Department, University General Hospital of Elche, Carrer Almazara, 11, 03203, Elche, Spain.
  • Amelin AV; Department of Neurology and Neurosurgery, Pavlov First Saint Petersburg State Medical University, Ulitsa L'va Tolstogo, 6-8, St. Petersburg, 197022, Russia.
  • Antonini A; Parkinson and Movement Disorders Unit, Department of Neuroscience, Padua University, Via VIII Febbraio, 2, 35122, Padua, Italy.
  • Bergmans B; Department of Neurology, AZ St-Jan Brugge-Oostende AV, Ruddershove 10, 8000, Brugge, Belgium.
  • Bergquist F; Department of Neurology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
  • Bouchard M; Department of Pharmacology, University of Gothenburg, Universitetsplatsen 1, 405 30, Gothenburg, Sweden.
  • Budur K; Clinique Neuro-Lévis, 1190 A Rue de Courchevel #301, Lévis, QC, G6W 0M5, Canada.
  • Carroll C; AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, USA.
  • Chaudhuri KR; Faculty of Health, University of Plymouth, Drake Circus, Plymouth, PL4 8AA, UK.
  • Criswell SR; Parkinson's Foundation International Centre of Excellence, King's College Hospital, Denmark Hill, London, SE5 9RS, UK.
  • Danielsen EH; King's College Institute of Psychiatry, Psychology and Neuroscience, 16 De Crespigny Park, London, SE5 8AF, UK.
  • Gandor F; Department of Neurology, Washington University in St. Louis, 1 Brookings Dr, St. Louis, MO, 63130, USA.
  • Jia J; Department of Neurology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark.
  • Kimber TE; Movement Disorders Hospital, Straße Nach Fichtenwalde 16, 14547, Beelitz-Heilstätten, Germany.
  • Mochizuki H; Department of Neurology, Otto-Von-Guericke University Magdeburg, Universitätspl. 2, 39106, Magdeburg, Germany.
  • Robieson WZ; AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, USA.
  • Spiegel AM; Department of Neurology, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia.
  • Standaert DG; Department of Medicine, University of Adelaide, 4 North Terrace, Adelaide, SA, 5000, Australia.
  • Talapala S; Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Facheris MF; AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, USA.
  • Fung VSC; AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, USA.
Neurol Ther ; 12(6): 1937-1958, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37632656
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Neurol Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Neurol Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos